4.7 Article

Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention

Journal

BLOOD
Volume 117, Issue 10, Pages 2975-2983

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-08-299974

Keywords

-

Categories

Funding

  1. Agence de la Biomedecine and Cent pour Sang la vie
  2. French government
  3. Association de recherche sur le cancer

Ask authors/readers for more resources

Recipient-specific regulatory T cells (rsTreg) can prevent graft-versus-host disease (GVHD) by inhibiting donor T-cell expansion after hematopoietic stem cell transplantation (HSCT) in mice. Importantly, in adult humans, because of thymus involution, immune reconstitution during the first months after HSCT relies on the peripheral expansion of donor T cells initially present in the graft. Therefore, we developed a mouse model of HSCT that excludes thymic output to study the effect of rsTreg on immune reconstitution derived from postthymic mature T cells present within the graft. We showed that GVHD prevention with rsTreg was associated with improvement of the limited immune reconstitution compared with GVHD mice in terms of cell numbers, activation phenotype, and cytokine production. We further demonstrated a preserved in vivo immune function using vaccinia infection and third-party skin-graft rejection models, suggesting that rsTreg immunosuppression was relatively specific of GVHD. Finally, we showed that rsTreg extensively proliferated during the first 2 weeks and then declined. In turn, donor Treg proliferated from day 15 on. Taken together, these results suggest that rsTreg GVHD prevention is associated with improved early immune reconstitution in a model that more closely approximates the biology of allogeneic HSCT in human adults. (Blood. 2011;117(10):2975-2983)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Cell Biology

NF-kappa B in Cancer Immunity: Friend or Foe?

Guilhem Lalle, Julie Twardowski, Yenkel Grinberg-Bleyer

Summary: NF-kappa B plays a crucial role in immune responses to cancer and could be targeted by novel immunotherapies.

CELLS (2021)

Review Nanoscience & Nanotechnology

Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option

Benedetta Ferrara, Sabrina Belbekhouche, Damien Habert, Claire Houppe, Benoit Vallee, Sandrine Bourgoin-Voillard, Jose L. Cohen, Ilaria Cascone, Jose Courty

Summary: Nanoparticles are being studied as a targeted delivery system for cancer treatment, with nucleolin identified as an interesting therapeutic target. Antagonists of nucleolin from various sources have shown promise as potential anti-cancer agents.

NANOTECHNOLOGY (2021)

Article Microbiology

Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19

Christophe Rodriguez, Nicolas de Prost, Slim Fourati, Claudie Lamoureux, Guillaume Gricourt, Melissa N'debi, Florence Canoui-Poitrine, Isaac Desveaux, Oriane Picard, Vanessa Demontant, Elisabeth Trawinski, Raphael Lepeule, Laure Surgers, William Vindrios, Jean-Daniel Lelievre, Nicolas Mongardon, Olivier Langeron, Jose L. Cohen, Armand Mekontso-Dessap, Paul-Louis Woerther, Jean-Michel Pawlotsky

Summary: This study utilized shotgun metagenomics and in-depth bioanalysis to investigate the role of viral genomics, microorganism metagenomics, and host transcriptomics in the severity of COVID-19. Severe COVID-19 pneumonia was associated with overexpression of cytokine transcripts activating the CXCR2 pathway, while patients with benign disease presented with a specific T cell profile and a lower mortality rate. Excess neutrophil infiltration leading to enhanced inflammatory response and prolonged tissue damage was identified as a key factor in the most severe cases of COVID-19. The study suggests that CXCR2 antagonists, especially IL-8 antagonists, could be promising candidates for treating severe COVID-19 patients.

PLOS PATHOGENS (2021)

Review Immunology

Strategies for Immunomonitoring after Vaccination and during Infection

Lucille Adam, Pierre Rosenbaum, Olivia Bonduelle, Behazine Combadiere

Summary: Immunomonitoring involves studying immune responses during vaccination or infection, with a focus on viral control or vaccine efficacy. Traditional methods include easy-to-use antibody-based technologies, while modern high-throughput technologies allow holistic approaches but also raise challenges in data integration methods and tools.

VACCINES (2021)

Article Immunology

Elevated Neopterin Levels Predict Fatal Outcome in SARS-CoV-2-Infected Patients

Manon Chauvin, Martin Larsen, Bibiana Quirant, Paul Quentric, Karim Dorgham, Luca Royer, Helene Vallet, Amelie Guihot, Behazine Combadiere, Christophe Combadiere, Jaume Barallat, Julien Mayaux, Charles-Edouard Luyt, Alexis Mathian, Zahir Amoura, Jacques Boddaert, Fernando Armestar, Guy Gorochov, Eva Martinez-Caceres, Delphine Sauce

Summary: This study found that severe and critically ill patients with SARS-CoV-2 infection exhibit exacerbated immune activation characterized by elevated neopterin blood levels. Systemic neopterin levels can serve as a biomarker of severe Covid-19, helping to identify high-risk populations.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Article Immunology

OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+T-Cells for Cross-Protection Against Influenza

Judith Del Campo, Julien Bouley, Marion Chevandier, Carine Rousset, Marjorie Haller, Alice Indalecio, Delphine Guyon-Gellin, Alexandre Le Vert, Fergal Hill, Sophia Djebali, Yann Leverrier, Jacqueline Marvel, Behazine Combadiere, Florence Nicolas

Summary: OVX836, a recombinant protein vaccine, induces a strong immune response through intramuscular injection, resulting in a high number of IFN- γ-producing CD8 + T-cells and lung TRM CD8 + T-cells for long-term protection against influenza viruses.

FRONTIERS IN IMMUNOLOGY (2021)

Article Immunology

LOX-1-Expressing Immature Neutrophils Identify Critically-Ill COVID-19 Patients at Risk of Thrombotic Complications

Behazine Combadiere, Lucille Adam, Noelline Guillou, Paul Quentric, Pierre Rosenbaum, Karim Dorgham, Olivia Bonduelle, Christophe Parizot, Delphine Sauce, Julien Mayaux, Charles-Edouard Luyt, Alexandre Boissonnas, Zahir Amoura, Valerie Pourcher, Makoto Miyara, Guy Gorochov, Amelie Guihot, Christophe Combadiere

Summary: Neutrophil subsets in COVID-19 patients have prognostic value in predicting disease severity and thrombosis complications.

FRONTIERS IN IMMUNOLOGY (2021)

Article Medicine, Research & Experimental

CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients

Lucille Adam, Pierre Rosenbaum, Paul Quentric, Christophe Parizot, Olivia Bonduelle, Noelline Guillou, Aurelien Corneau, Karim Dorgham, Makoto Miyara, Charles-Edouard Luyt, Amelie Guihot, Guy Gorochov, Christophe Combadiere, Behazine Combadiere

Summary: This study identified specific T cell populations associated with survival or death in COVID-19 patients in intensive care, providing potential targets for T cell-based vaccine development and disease outcome prediction.

JCI INSIGHT (2021)

Editorial Material Medicine, Research & Experimental

Inhibition of anti-tumor immunity by NF-κB: Toward therapeutic targeting?

Lara Revol-Bauz, Yenkel Grinberg-Bleyer

M S-MEDECINE SCIENCES (2022)

Review Cell Biology

The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response

Audrey Moatti, Jose L. Cohen

Summary: Newly discovered anti-cancer immunotherapies focus on stimulating anti-tumor T cell responses, but a significant proportion of patients do not respond. A novel approach proposes targeting the suppressive action of Tregs on anti-tumoral responses. TNFR2 has emerged as a legitimate target for anti-cancer immune checkpoint therapy, showing potential in overcoming the immune suppression in cancer patients.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Oncology

ZEB1 transcription factor promotes immune escape in melanoma

Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, Brigitte Balme, Garance Tondeur, Arnaud de la Fouchardiere, Lionel Larue, Alain Puisieux, Yenkel Grinberg-Bleyer, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Stephane Dalle, Julie Caramel

Summary: This study reveals that ZEB1 expression in melanoma cells is associated with decreased CD8(+) T cell infiltration, leading to tumor immune evasion and resistance to immune checkpoint blockade. ZEB1 directly represses the secretion of T cell-attracting chemokines, such as CXCL10, and targeting ZEB1 may enhance the efficacy of immunotherapy in melanoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression

Matteo Ponzo, Anais Debesset, Melissande Cossutta, Mounira Chalabi-Dchar, Claire Houppe, Caroline Pilon, Alba Nicolas-Boluda, Sylvain Meunier, Fabio Raineri, Allan Thiolat, Remy Nicolle, Federica Maione, Serena Brundu, Carina Florina Cojocaru, Philippe Bouvet, Corinne Bousquet, Florence Gazeau, Christophe Tournigand, Jose Courty, Enrico Giraudo, Jose L. Cohen, Ilaria Cascone

Summary: This study explores the effects of a selective inhibitor of nucleolin (NCL) on the immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), and highlights a new therapeutic strategy to restrain immunosuppressive cells, promote T-cell recruitment and activation, and re-program the tumor stroma of PDAC.

CANCERS (2022)

Article Oncology

MDR1-EXPRESSING CD4+ T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE

Anthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Celine Rodriguez, Yenkel Grinberg-Bleyer, Guilhem Lalle, Lyvia Moudombi, Raphael Schneider, Cyril Degletagne, Isabelle Treilleux, Daniel J. Campbell, Severine Metzger, Thomas Duhen, Olivier Tredan, Christophe Caux, Christine Menetrier-Caux

Summary: This study investigated the expression, function, and regulation of MDR1 in CD4(+) T cells and its role in neoadjuvant chemotherapy in breast cancer. The results showed that MDR1 expression was associated with the enrichment of Th1.17 and Th17 cells and correlated positively with pathological response. This study has important clinical implications for adjusting chemotherapy regimens.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

What role for AHR activation in IL4I1-mediated immunosuppression ?

Flavia Castellano, Armelle Prevost-Blondel, Jose L. Cohen, Valerie Molinier-Frenkel

Summary: Although IL4I1 has emerged as a relevant therapeutic target for cancer, its precise role remains poorly understood. IL4I1 inhibits TCR signaling, modulates T cell differentiation, limits T cell proliferation, and shapes the tumor microenvironment in a way that impairs the antitumor immune response. The production of new IL4I1 metabolites may play a role in activating the aryl-hydrocarbon receptor (AHR), but the correlation between IL4I1 expression and AHR activation in human cancers is weak.

ONCOIMMUNOLOGY (2021)

Meeting Abstract Immunology

Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption

B. Oriol-Tordera, A. Esteve-Codina, M. Berdasco, E. Goncalves, M. Esteller, T. Hanke, J. Molto, B. Clotet, M. L. Calle, B. Combadiere, A. Sanchez-Pla, B. Mothe, M. Ruiz-Riol, C. Brander

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)

No Data Available